Zum Hauptinhalt springen
CAS 1 Eintrag

CAS 113-45-1

CAS 113-45-1 entspricht 1 EU-Anhangseintrag in den Anhängen II–VI der Verordnung (EG) Nr. 1223/2009.

Einträge zu CAS 113-45-1

1 insgesamt

Chemische Identität und Eigenschaften

Chemische 2D-Struktur aus PubChem für CAS 113-45-1
CAS 113-45-1PubChem CID 4158

Methylphenidate

Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a methyl ester, a member of piperidines and a beta-amino acid ester. — ChEBI

IUPAC-Name
methyl 2-phenyl-2-piperidin-2-ylacetate
Summenformel
C14H19NO2
Molekulargewicht
233.31 g/mol
Exakte Masse
233.141578849 Da
XLogP3
0,2
Topologische polare Oberfläche
38,3 Ų
Wasserstoffbrücken-Donoren
1
Wasserstoffbrücken-Akzeptoren
3
Kovalente Einheiten
1
Definierte Stereozentren
0

Auch bekannt als

MethylphenidanPhenidylateCalocainPlimasineMethyl phenidylacetateMetilfenidatoMethylphenidatumMethyl phenidate
16 weitere gemeldete Namen
4311/B CibaDaytranaalpha-Phenyl-2-piperidineacetic acid methyl esterMethyl alpha-phenyl-alpha-(2-piperidyl)acetateNCI-C56280Methyl 2-phenyl-2-(piperidin-2-yl)acetate2-Piperidineacetic acid, alpha-phenyl-, methyl esterCotempla XR-ODTMethyl alpha-phenyl-alpha-2-piperidinylacetatealpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl esterMetilfenidat hydrochlorideThreo-dl-methylphenidatePrc-063Methylphenidate extended releaseRitalineRefChem:6033
Kennungen in externen Datenbanken

Belege aus weiteren wissenschaftlichen Datenbanken

NIH PubChem PUG-View
Exakter Kennungstreffer4158

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. Quelle: Toxin and Toxin Target Database (T3DB)
  • Signal: Warning Quelle: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] Quelle: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement) Quelle: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. Quelle: European Chemicals Agency (ECHA)
  • Signal: Danger Quelle: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Quelle: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P264, P270, P271, P284, P301+P317, P304+P340, P330, P342+P316, P403, and P501 (click each P-code to see the statement) Quelle: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. Quelle: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Methylphenidate Hydrochloride is a psychostimulant used to treat different behavioral disorders. Indications: Used to treat narcolepsy and hyperkinetic states in children (as an adjunct to psychological, educational and social measures) for amphetamine, dextroamphetamine and ethylphenidate. It is misused for performance enhancement and relief of fatigue. Abuse either orally or by injection is extremely common. HUMAN EXPOSURE AND TOXICITY: Main risks include: Acute central nervous system (CNS) stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Cardiovascular effects include: palpitation, chest pain, tachycardia, arrhythmias and hypertension; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. CNS effects include: stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia. Stroke and cerebral vasculitis have been observed. Gastrointestinal effects include: vomiting, diarrhea and cramps. Genitourinary effects include: incre Quelle: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present. Quelle: StatPearls
  • Toxicity Summary: Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result. Quelle: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for methylphenidate(SRC), using a log Kow of 0.20(1) and a regression-derived equation(2). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). Quelle: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to have low mobility in soil(SRC). The pKa of methylphenidate is 8.9(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species of methylphenidate from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Methylphenidate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015). Quelle: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.9(5) indicates methylphenidate will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.20(7) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Base-catalyzed second-order hydrolysis rate constant half-lives of 23 and 2.3 years at pH values of 7 and 8, respectively(2), suggest that hydrolysis may be a slow environmental fate process. Biodegradation data in water were not available(SRC, 2015). Quelle: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), methylphenidate, which has an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase methylphenidate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 1 hr(SRC), calculated from its rate constant of 1.1X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase methylphenidate may be removed from the air by wet and dry deposition(SRC). Methylphenidate contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Methylphenidate (DEA Code Number: 1724) is a Schedule II controlled substance. Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence. Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION (VET) Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Central Nervous System Stimulants; Dopamine Uptake Inhibitors Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >250; Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 9090; Consumption (g per capita) in Switzerland (2009): 0.032; Consumption (g per capita; approx.) in Germany (2009): 0.012; Consumption (g per capita) in the USA (2002): 0.032; Excretion rate: 0.1; Calculated removal (%): 92.1 Quelle: NORMAN Suspect List Exchange
  • Uses: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Quelle: Toxin and Toxin Target Database (T3DB)

Zugeordnet durch: Existing checksum-valid CAS to unique PubChem CID match. Abgerufen: 2026-08-31. Quelleneintrag öffnen

Wissenschaftliche Klassifizierungen und Gefahrenannotationen liefern Kontext und ersetzen nicht die oben gezeigte marktspezifische regulatorische Entscheidung.

Weitere Quellenabdeckung und Trefferstatus
QuelleErgebnisGeprüft
NIH PubChem PUG-ViewExakter Treffer2026-08-31

Ein erfasster Nicht-Treffer ist ein nützlicher Beleg dafür, dass die Quelle geprüft wurde; er ist keine Behauptung, dass der Stoff anderswo nicht existiert.

Am 2026-09-02 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.

Wie CAS 113-45-1 auf dieser Website verwendet wird

CAS 113-45-1 ist die Kennung des Chemical Abstracts Service, mit der diese Seite einem bestimmten Stoff zugeordnet wird. Im aktuellen Datenbestand hat 1 EU-Anhangseintrag diese Kennung; so können Sie gegenprüfen, ob derselbe Stoff in einem oder in mehreren regulatorischen Zusammenhängen auftaucht.

Nutzen Sie diese Seite, wenn eine Lieferantenspezifikation, ein Sicherheitsdatenblatt oder ein Rohstoffdossier CAS 113-45-1 nennt und Sie alle verknüpften Einträge der Anhänge II–VI an einem Ort sehen möchten. Die Eintragskarten oben sind der schnellste Weg zu Konzentrationsgrenzen, Warnhinweisen, Anhangszuordnung und Produktartbedingungen.

Häufig gestellte Fragen

Ein durch CAS 113-45-1 identifizierter Stoff kann in mehreren Anhängen der EU-Kosmetikverordnung vorkommen, wenn er in unterschiedlichen Zusammenhängen unterschiedlichen Bedingungen unterliegt. Ein Stoff kann beispielsweise nach Anhang III mit bestimmten Bedingungen beschränkt sein, und dieselbe CAS-Nummer kann auch in Anhang IV als zugelassener Farbstoff unter eigenen Eintragsbedingungen erscheinen. Jeder Eintrag muss einzeln geprüft werden.

Gleichen Sie die CAS-Nummer mit den Spezifikationsblättern und Analysenzertifikaten Ihrer Rohstoffe ab. Erscheint eine CAS-Nummer in Anhang II, prüfen Sie die Abwesenheit des Stoffs. Erscheint sie in Anhang III, prüfen Sie, ob Konzentrationsgrenzen und Produktartbedingungen in Ihrer Rezeptur eingehalten werden. Alle Anhangseinträge mit dieser CAS-Nummer sind oben aufgeführt.

Eine CAS-Nummer wird vom Chemical Abstracts Service (USA) vergeben und ist weltweit anerkannt. Eine EC-Nummer ist eine Kennung der Europäischen Kommission aus Verzeichnissen wie EINECS, ELINCS oder der NLP-Liste. Beide Kennungen können in Einträgen der EU-Kosmetikanhänge vorkommen. Manche Stoffe haben beide, manche nur eine, und einige ältere Einträge haben möglicherweise keine von beiden.

Der INCI-Checker akzeptiert Inhaltsstoffnamen, CAS-Nummern und EC-Nummern. Prüfen Sie diese CAS-Nummer direkt und gleichen Sie das Ergebnis anschließend mit den Spezifikationsblättern der Lieferanten und allen verknüpften Anhangsbedingungen ab.

Werkzeuge und nächste Schritte

Rezeptur prüfen

Eine vollständige INCI-Liste prüfen und anschließend mit CAS 113-45-1 Lieferantendokumente zu den gefundenen Stoffen gegenprüfen.

INCI-Checker

Anhänge durchsuchen

Alle Anhänge der EU-Kosmetikverordnung nach Kategorie durchsuchen.

Alle Anhänge

Nach Name suchen

Nach INCI-Namen, Aliasen oder verwandten Kennungen suchen, die in Ihrer Dokumentation neben CAS 113-45-1 stehen.

Suche